Tolero Pharmaceuticals (United States)

Recent papers from Tolero Pharmaceuticals (United States)

1. Targeting TGFBR1 with the Investigational Inhibitor TP-6379 Improves Hematopoiesis in Low-Risk MDS Ex VivoCells · 2026
2. Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistanceBlood Cancer Journal · 2021
3. Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancerBJUI Compass · 2020
4. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019Journal of the National Comprehensive Cancer Network · 2019
5. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapyOncotarget · 2018
6. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription FactorsSLAS DISCOVERY · 2018
7. Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.2018
8. Combined venetoclax and alvocidib in acute myeloid leukemiaOncotarget · 2017
9. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple CancersMolecular Cancer Research · 2016
10. Phenotypic chemical screening using zebrafish neural crest reporters identifies retinoid acid as an inhibitor of epithelial morphogenesisDisease Models & Mechanisms · 2016
11. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK InhibitorsClinical Cancer Research · 2015
12. Activators of PKM2 in Cancer MetabolismFuture Medicinal Chemistry · 2014
13. A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial CarcinomasNeoplasia · 2014
14. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl KinaseCancer Research · 2013
15. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceClinical Cancer Research · 2012